SecBot SecBot

PRQR

ProQR Therapeutics N.V.
Nasdaq· Pharmaceutical Preparations· CIK 0001612940 Biotech & Drug Discovery
$1.34 +0.10 (+7.66%)
Oct 27 4:00 PM ET · prev $1.24
Market cap
$182.0M
Micro cap
Consensus
Buy
94% Buy or better · 16 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 5
in 9 days · EPS est. −$0.11
1 year
−53.3%
from $2.86 · Oct 27
30 days
−19.1%
from $1.65
52-week range
$1.24–2.86
−53% from high · low Oct 26
Avg volume 20D
974.3K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$1.3M
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·Next Earnings date, Nov 5, 2026
Strongest NEUTRAL ProQR announced the appointment of Chris Hart (ex-Eli Lilly VP of Data Science) as Chief Data and AI Officer…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $1.3M at an average $1.68. No open-market sales. Price is 20% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 11 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    15 of 16 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.137 → −$0.106 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    26% below its 50-day average. New closing low $1.24 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ADAGE CAPITAL PARTNERS GP, L.L.C.ADD9,015,897$16.8M
Aberdeen Group plcDOUBLED8,932,507$16.6M
MORGAN STANLEYADD1,767,215$3.3M
CITADEL ADVISORS LLCADD1,184,314$2.2M
UBS Group AGDOUBLED639,243$1.2M
JANE STREET GROUP, LLCDOUBLED455,104$846.5K
BNP PARIBAS FINANCIAL MARKETSADD275,631$512.7K
Quadrature Capital LtdDOUBLED84,806$157.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 94% rate it Buy or better
Strong Buy6Buy9Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 1, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Oct 1, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 20, 2026B of A Securities
INITIATE
INITIATEBuy
Jun 29, 2026Evercore ISI Group
MAINTAIN
MAINTAINOutperform
Jun 26, 2026Jones Trading
MAINTAIN
MAINTAINBuy
Jun 26, 2026Chardan Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$1.3M
bought · 2 insiders
$0
sold · 0 insiders
−20.4%
vs their $1.68 cost
DateInsiderTypeValue
Jul 31, 2026
de Boer Daniel Anton
Chief Executive Officer
BUY$354.0K
Jul 17, 2026
Filius Bart
Director
BUY$257.9K
Jul 9, 2026
de Boer Daniel Anton
Chief Executive Officer
BUY$261.0K
Jul 7, 2026
de Boer Daniel Anton
Chief Executive Officer
BUY$238.5K
Jun 26, 2026
Filius Bart
Director
BUY$231.0K
Jun 2, 2026
Hinsch Gylvin Lykke
Director
AWARD14,595 sh
Jun 2, 2026
Hinsch Gylvin Lykke
Director
AWARD14,495 sh

Earnings setup

Estimates
Nov 5
reports in 9 days
−$0.11
EPS estimate, this quarter
+23%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.11-$0.11–-$0.10+1.9%$4.9M
Next Q-$0.13-$0.18–-$0.09+2.2%$4.9M
Current FY-$0.45-$0.53–-$0.38+2.1%$20.5M
Next FY-$0.46-$0.54–-$0.39+2.1%$18.4M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 SEC
ProQR announced the appointment of Chris Hart (ex-Eli Lilly VP of Data Science) as Chief Data and AI Officer and…
6-K — Impact 4/10
Sep 9, 2026 SEC
ProQR announced the first participant dosed in the Phase 1 study of AX-0811, a next-generation RNA editing…
6-K — Impact 4/10
Sep 9, 2026 Announcement
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (
Jul 31, 2026 Insider
de Boer Daniel Anton bought 200,000 shares
Chief Executive Officer @ $1.77 ($354.0K)
Jul 17, 2026 Insider
Filius Bart bought 150,000 shares
Director @ $1.72 ($257.9K)
Jul 16, 2026 SEC
ProQR Therapeutics N.V. received SEC effectiveness on July 15, 2026 for its F-3 shelf registration (File No…
EFFECT — Impact 5/10
Jul 9, 2026 Insider
de Boer Daniel Anton bought 150,000 shares
Chief Executive Officer @ $1.74 ($261.0K)
Jun 30, 2026 Inst.
ADAGE CAPITAL PARTNERS GP, — ADD
9,015,897 shares ($16.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
PRQR Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Sep 9, 2026
Announcement
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company…
Jul 30, 2026
Earnings date
PRQR Q2 2026 Earnings Scheduled — 2026-07-30
Jun 25, 2026
Announcement
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage…
Jun 25, 2026
Announcement
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR or the Company), a…
May 6, 2026
Earnings date
PRQR Q1 2026 Earnings Scheduled — 2026-05-06

SecBot reports

10 filings · 4 press releases · 2 bullish · 3 bearish · 1 mixed · 4 neutral
All PRQR filing & press-release reports (14)